Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Leuprolide |
Synonyms | |
Therapy Description |
Lupron (leuprolide) is an agonist of gonadotropin releasing hormone (GnRH), which results decreased testosterone production in males and decreased estradiol production in females, potentially leading to decreased growth of androgen-positive tumors (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Leuprolide | Lupron | Leuprorelin | Lupron (leuprolide) is an agonist of gonadotropin releasing hormone (GnRH), which results decreased testosterone production in males and decreased estradiol production in females, potentially leading to decreased growth of androgen-positive tumors (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00541047 | Phase III | Leuprolide Goserelin Bicalutamide | Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) | Completed | GBR | CAN | 0 |
NCT02064582 | Phase II | Leuprolide Enzalutamide | Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer | Completed | USA | 0 |
NCT04557059 | Phase III | Apalutamide + Triptorelin Triptorelin Apalutamide + Goserelin Apalutamide + Leuprolide Leuprolide Goserelin | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants (PRIMORDIUM) | Active, not recruiting | USA | TUR | SWE | SVK | POL | LBN | ITA | HUN | FIN | ESP | DNK | DEU | CZE | BRA | BEL | AUT | AUS | 4 |
NCT04484818 | Phase III | Goserelin Leuprolide Darolutamide + Leuprolide Darolutamide + Triptorelin Triptorelin Darolutamide + Goserelin | Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study | Active, not recruiting | USA | 0 |
NCT03678025 | Phase III | Docetaxel Nilutamide Triptorelin Bicalutamide Leuprolide Degarelix Goserelin Flutamide Prednisone Abiraterone Histrelin acetate | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Recruiting | USA | CHE | 3 |
NCT02064036 | Phase I | Bicalutamide Goserelin Leuprolide | Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate | Completed | USA | 0 |
NCT02278185 | Phase II | Goserelin Degarelix Histrelin acetate Triptorelin Leuprolide Enzalutamide | Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03511196 | Phase I | Abiraterone + Prednisone Leuprolide Goserelin Triptorelin | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02319837 | Phase III | Leuprolide Enzalutamide | Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | Active, not recruiting | USA | SWE | SVK | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | CAN | BRA | AUT | AUS | 2 |
NCT02811809 | Phase II | Leuprolide Apalutamide + Leuprolide | Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer | Withdrawn | USA | 0 |
NCT00223665 | Phase II | Leuprolide Flutamide | Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy | Completed | USA | 0 |
NCT02023463 | Phase I | Goserelin Enzalutamide Leuprolide | Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04787744 | Phase II | Goserelin Degarelix Relugolix Nilutamide Triptorelin Histrelin acetate Docetaxel + Prednisone Leuprolide Apalutamide Abiraterone + Prednisone Flutamide Abiraterone + Methylprednisolone Bicalutamide Docetaxel Enzalutamide | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT) | Recruiting | USA | 0 |
NCT04302454 | Phase III | Leuprolide | Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy (ADOPT) | Recruiting | NLD | 0 |
NCT02268175 | Phase II | Enzalutamide Abiraterone Prednisone Leuprolide | Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | Completed | USA | 0 |
NCT03085095 | Phase III | Relugolix Leuprolide | A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO) | Completed | USA | SWE | SVK | POL | NZL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS | 4 |
NCT01717053 | Phase II | Leuprolide Abiraterone Prednisone Goserelin | Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer | Completed | USA | 0 |
NCT02472275 | Phase I | Leuprolide Pexidartinib Goserelin Degarelix | PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer | Completed | USA | 0 |
NCT02941926 | Phase III | Letrozole + Ribociclib Leuprolide Goserelin | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC | Completed | USA | SWE | SVN | SVK | POL | NOR | NLD | LBN | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CAN | BGR | BEL | AUT | ARG | 15 |
NCT02736435 | Phase III | Leuprolide | Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound | Withdrawn | CAN | 0 |
NCT02057939 | Phase II | Enzalutamide Leuprolide | Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) | Completed | USA | 0 |
NCT06397703 | Phase III | Leuprolide Degarelix Relugolix | ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer | Recruiting | USA | 0 |
NCT03261999 | Phase III | Leuprolide | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer | Completed | USA | SVK | LTU | CZE | 1 |
NCT01338987 | Phase II | Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | Completed | USA | 0 |
NCT03573648 | Phase II | Leuprolide Avelumab + Palbociclib + Tamoxifen Avelumab + Tamoxifen Leuprolide + Palbociclib Avelumab + Leuprolide Avelumab + Leuprolide + Palbociclib Tamoxifen Goserelin Palbociclib + Tamoxifen Avelumab + Goserelin Goserelin + Palbociclib Avelumab + Goserelin + Palbociclib | Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT) | Active, not recruiting | USA | 0 |
NCT02366494 | Phase I | Leuprolide Goserelin Triptorelin Bicalutamide Docetaxel | Micro RNAs to Predict Response to Androgen Deprivation Therapy | Active, not recruiting | USA | 0 |
NCT02058706 | Phase II | Goserelin Bicalutamide Enzalutamide Leuprolide | LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer | Completed | USA | 0 |
NCT01746849 | Phase II | Leuprolide Cyclophosphamide Thiotepa Palifermin | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT02059213 | Phase II | Goserelin Palbociclib Bicalutamide Leuprolide | A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer | Completed | USA | 0 |
NCT04423211 | Phase III | Apalutamide + Leuprolide Apalutamide + Goserelin Leuprolide Goserelin | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Using PET/CT Imaging | Recruiting | USA | 0 |
NCT03809000 | Phase II | Goserelin Bicalutamide Enzalutamide Leuprolide | A Trial to See What the Results Are for Radiation Therapy and Hormone Therapy vs Radiation Therapy With Enhanced Hormone Therapy With Enzalutamide for Patients With PSA Recurrence After Surgery (STEEL) | Active, not recruiting | USA | CAN | 0 |
NCT03944434 | Phase II | Anastrozole + Ribociclib Letrozole + Ribociclib Leuprolide Goserelin Triptorelin | FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (FACILE) | Active, not recruiting | ITA | 0 |
NCT02689921 | Phase II | Anastrozole Letrozole Leuprolide Pertuzumab + Trastuzumab Exemestane | NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT) | Unknown status | USA | 0 |
NCT02663908 | Phase III | Degarelix Leuprolide | A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease | Terminated | USA | SVK | POL | GRC | GBR | FRA | FIN | DEU | CZE | CAN | 2 |
NCT02234115 | Phase III | Leuprolide | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma | Completed | USA | SVK | POL | LTU | DEU | CZE | AUT | 1 |
NCT06378866 | Phase II | Degarelix Goserelin Darolutamide Relugolix Triptorelin Enzalutamide Histrelin acetate Abiraterone + Prednisone Leuprolide Apalutamide | Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE) | Recruiting | USA | 0 |
NCT01786265 | Phase II | Goserelin Degarelix Abiraterone Prednisone Leuprolide | Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone | Active, not recruiting | USA | 0 |
NCT06654336 | Phase II | Leuprolide | Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) (RATIONAL-PCS) | Not yet recruiting | CAN | 0 |
NCT03279250 | Phase II | Goserelin Triptorelin Abiraterone + Apalutamide + Prednisone Leuprolide Apalutamide | Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence | Completed | USA | 0 |
NCT02346253 | Phase Ib/II | Leuprolide Triptorelin Degarelix Bicalutamide Goserelin | High-Dose Brachytherapy in Treating Patients With Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04126070 | Phase II | Docetaxel + Nivolumab Leuprolide Goserelin Degarelix | Nivolumab + Docetaxel + ADT in Metastatic Hormone Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03093272 | Phase II | Leuprolide Prednisone Apalutamide + Docetaxel | A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer | Terminated | USA | 0 |
NCT04331717 | Phase II | Leuprolide | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer (BASH-PC) | Withdrawn | USA | 0 |
NCT05169112 | Phase III | Leuprolide | Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | Recruiting | CAN | 0 |
NCT03899077 | Phase II | Triptorelin Goserelin Degarelix Leuprolide Apalutamide | Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (SAVE) | Recruiting | BEL | 0 |
NCT01674140 | Phase III | Goserelin Anastrozole Letrozole Leuprolide Everolimus Tamoxifen Exemestane | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3) | Active, not recruiting | USA | 1 |
NCT00936390 | Phase III | Flutamide Goserelin Leuprolide Triptorelin Bicalutamide | Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer | Active, not recruiting | USA | CAN | 0 |
NCT02685397 | Phase II | Enzalutamide Triptorelin Goserelin Leuprolide | Management of Castration-Resistant Prostate Cancer With Oligometastases | Recruiting | CAN | 0 |
NCT02972060 | Phase II | Triptorelin Leuprolide Degarelix Goserelin Darolutamide | ODM-201 vs Androgen Deprivation Therapy in Hormone naive Prostate Cancer | Active, not recruiting | ITA | FRA | ESP | BEL | 0 |
NCT05050084 | Phase III | Buserelin Relugolix Degarelix Goserelin Leuprolide Histrelin acetate Triptorelin Darolutamide + Goserelin Bicalutamide Darolutamide + Degarelix Darolutamide + Leuprolide Darolutamide + Triptorelin Buserelin + Darolutamide Darolutamide + Histrelin acetate Flutamide Darolutamide + Relugolix | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | Recruiting | USA | CAN | 0 |
NCT06282588 | Phase II | Docetaxel Leuprolide Degarelix Goserelin Triptorelin Darolutamide | Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) | Recruiting | BEL | 0 |